Lv7
4520 积分 2023-10-08 加入
Results of Switching From Tofacitinib to Upadacitinib in Patients With Atopic Dermatitis: A Retrospective Medical Record Review
1个月前
已关闭
Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity
1个月前
已完结
Atopic dermatitis
2个月前
已完结
The era of advanced therapeutics for pediatric atopic dermatitis – can early systemic intervention reduce the type 2 inflammatory response and modify the atopic march?
2个月前
已关闭
Deconstruction of immune-mediated skin diseases defines six inflammatory subtypes
2个月前
已完结
[Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors]
3个月前
已完结
Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
3个月前
已完结
Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study
7个月前
已完结
Reading the palms: Palmar hyperlinearity and type 2 biomarkers as early predictors of atopic dermatitis onset in infancy?
7个月前
已关闭
Treatment of refractory progressive vitiligo with oral upadacitinib and narrow‐band ultraviolet‐B: A case series
10个月前
已完结
皖公网安备34019202002308
